What is Aerolase?
Aerolase stands as a global technology leader in laser skin health, uniquely manufacturing portable high-power lasers for dermatology and aesthetics. Its innovative technology enhances treatment outcomes, safety, and patient experience across all skin types by minimizing discomfort and downtime. The company's signature #NoTouchAerolase approach offers a contactless, hygienic solution for medical aesthetics. Beyond patient care, Aerolase empowers physicians to practice modern medicine profitably and reduce overall healthcare costs. The company's laser systems address a wide spectrum of dermatological and aesthetic conditions, including acne, melasma, psoriasis, onychomycosis, wound healing, and general skin rejuvenation.
How much funding has Aerolase raised?
Aerolase has raised a total of $2.2M across 2 funding rounds:
Debt
$1M
Debt
$1.2M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.2M led by PPP
Key Investors in Aerolase
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Aerolase?
The recent major strategic investment indicates Aerolase is poised for accelerated expansion and further technological development. This capital infusion is likely to fuel advancements in its proprietary laser technology, potentially leading to new applications or enhanced efficacy for existing treatments. The company's focus on improving patient comfort and physician profitability, coupled with its ability to treat diverse skin conditions, positions it for continued market leadership and potential global scaling. Future endeavors may involve expanding its product portfolio, increasing market penetration in existing regions, and exploring new international territories.
See full Aerolase company page
